Receive The Newest Study Notifications

BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

BXCL701 may improve patient response when combined with checkpoint inhibitors or re-sensitize patients who have failed checkpoint therapy NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a...

Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

INDIANAPOLIS, Dec. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung...

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

 Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304). RELIEF is a potential pivotal study of TNX-102 SL*...

Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

The RECOVER™ study is assessing real-world, patient-centered outcomes including abstinence from illicit opioids and life changes, such as improved health, employment status and connection to community following treatment with SUBLOCADE™ (Buprenorphine...

GIOSTAR in Process of US FDA Approval for Type 2 Diabetes Clinical Trial

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Groundbreaking study by pioneer in stem cell research may potentially save millions of lives SAN DIEGO, Dec. 10, 2019 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the leader in regenerative technologies, is proud to announce that...

Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– Company expects to initiate Phase 2 clinical trial in patients with phenylketonuria in 1H 2020 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...